Drawing for AKTX

USPTO serial 99290379

AKTX

Reviewed by CopyMark Law Group

Status 730Notice of Allowance
Filing date
Status date
Registration date
—
Examiner
MASON, JARED MICHAEL
Law office
INTENT TO USE SECTION

What this means

The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.

Status 730: Status 730 means you filed the first six-month extension to delay filing a Statement of Use after a Notice of Allowance. You must file a Statement of Use or another extension before the new deadline.

Need help with AKTX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,545*

Plus Government fees of $750

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Michael T. Smith

Michael T. Smith Birch Stewart Kolasch & Birch, LLP2600 Park Tower Drive, Suite 600Vienna, VA 22180United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for skin wounds; Preparations for the treatment of burns; Pharmaceutical preparations for the treatment of cardiovascular disease and cerebrovascular disease; Pharmaceutical preparations for the treatment of neurological diseases; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of osteoporosis; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of rheumatism; Fever blister treatment preparations; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the treatment of organ transplant; Preparation for the relief of pain; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of kidney diseases; Diuretic preparations; immunosuppressive preparations; drug delivery agents in the form of solutions, compounds, powders, and tablets that facilitate delivery of a wide range of pharmaceuticals and provide controlled and sustained release of the active ingredients for a wide variety of pharmaceuticals; Antidepressants; Pharmaceutical preparations for use in urology; pharmaceutical preparations for use in rheumatology; pharmaceutical preparations for use in nephrology; Pharmaceutical preparations used in organ transplantation; pharmaceutical preparations for use in hematology; pharmaceutical preparations for use in orthopedics; pharmaceutical preparations for use in pulmonology; Diagnostic agents, preparations and substances for medical purposes; Nutritional supplements; medical preparations for dental purposes, namely, dental preparations for disclosing plaque; Medicated toothpaste; Antifungal creams for medical use; Antifungal preparations; Chinese traditional medicinal herbs; Dietetic preparations adapted for medical purposes; Medical dressings; Wound dressings; Capsules sold empty for pharmaceuticals; dental composite materials; Dietary supplements; Pharmaceutical preparations for the treatment of hematologic disordersACTIVE—
010Heart rate monitors; Blood oxygen monitors; Blood pressure monitors; Respiration monitors; Surgical needles; Surgical pliers; Medical and surgical catheters; Stretchers for patient transport; Artificial limbs; Artificial teeth; medical apparatus and instruments for use in surgery and companion diagnostics, namely, for detecting cancer, for testing for viruses, for analyzing and measuring electrolytes in the body, for detecting and measuring antibody levels, and for detecting and measuring pathogenic proteins, lipids, and carbohydrates; Body rehabilitation apparatus for medical purposes; orthopedic apparatus and instruments for diagnostic and therapeutic use; Surgical gowns; Surgical capsACTIVE—
041arranging, conducting and organization of seminars in the field of medicine, pharmaceuticals, health, healthcare; arranging, conducting and organization of seminars, workshops, lectures and congresses, all in the field of medicine, pharmaceuticals, health, healthcareACTIVE—
042design and development of medical diagnostic apparatus; design and development of medical technology in the nature of medical software; computer programming for the medical sector; design and development of computer software for use with medical technology; Testing, inspection or research of pharmaceuticals, cosmetics or foodstuff; research and development of medicines and pharmaceuticals; provision of information and data relating to medical and pharmaceutical research and development; consultancy relating to medical and pharmaceutical research and development; Scientific and technological services, namely, scientific research, analysis and testing in the field of medicine, pharmacology, biotechnology and bacteriology; provision of information and data relating to scientific and technological research and development; consultancy in the field of scientific research; Scientific testing and research in the field of medical machines, apparatus and instrumentsACTIVE—
044Provision of medical information; providing information in the field of medical and diagnostic, prophylactic, and therapeutic properties of pharmaceuticals; Medical and pharmaceutical consultationACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 5, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Nov 4, 2026EX1GSOU EXTENSION 1 GRANTED—
Nov 4, 2026EXT1SOU EXTENSION 1 FILED—
Nov 4, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 19, 2026NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Mar 24, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 24, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 18, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 26, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 26, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 26, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 26, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 8, 2025GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 8, 2025GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 8, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 5, 2025DOCKASSIGNED TO EXAMINER—
Nov 24, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 18, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Jul 18, 2025NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance